Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints to support a Phase III trial and FDA marketing application.